The effects of insulin pump therapy on an individual's physical & psychological well-being and cognition.

Not Applicable

Recruiting

• Conditions: Type 1 diabetes; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12610000296033
• Lead Sponsor: Medtronic

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-04-13
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with Type 1 Diabetes commencing CSII therapy
Age 18 years to 69 years
The capacity to give and accept informed consent to participate in the research

Exclusion Criteria

Age under 18 years or >=70 years
Chronic renal disease, stage III or IV
Psychosis or psychiatric disorder
Active cancer within last 5 years
Inability to provide informed consent (i.e. has an intellectual disability, dementia)
Unable to communicate in English

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary Endpoint: Glycated haemoglobin (HbA1c). We expect improvements in HbA1c from pre-CSII commencement to three and six-month post commencement.[Baseline, three months and six months follow-up]

Secondary Outcome Measures

Name	Time	Method
Improvement in physical and emotional quality of life using validated questionnaires[Baseline, three months and six months follow-up];Improvement in cognition with more stable blood sugar levels. It will be measured using a validated questionnaire.[Baseline, three months and six months follow-up]